Form 4: Fairmount Funds Acquires Shares in Oruka Therapeutics via Private Placement

Fairmount Funds Management and related entities report acquisition of common stock and convertible preferred stock in Oruka Therapeutics through a private placement.

Summary

• Fairmount Funds Management LLC, along with Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest III L.P., Tomas Kiselak, and Peter Harwin, filed a Form 4 detailing changes in beneficial ownership of Oruka Therapeutics, Inc. [ORKA] securities.
• The transactions involve the acquisition of 275,000 shares of common stock and 160 shares of Series A Non-Voting Convertible Preferred Stock through a private placement on September 11, 2024.
• The shares were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.
• The Series A Preferred Stock is convertible into common stock at a rate of 1,000 shares of common stock per share of preferred stock, subject to a 9.99% ownership limitation.
• Fairmount Funds Management LLC is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P.
• Peter Harwin and Tomas Kiselak are managing members of Fairmount Funds Management GP LLC, the general partner of Fairmount Funds Management LLC.
• Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest therein.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of shares by Fairmount Funds indicates confidence in the company. However, the disclaimer of beneficial ownership by certain parties tempers the positive sentiment.

Positives

• The private placement indicates confidence in Oruka Therapeutics' future prospects from Fairmount Funds Management.
• The acquisition of convertible preferred stock provides potential for future conversion into a significant number of common shares.

Future Outlook

The document does not contain explicit forward-looking statements, but the conversion of preferred stock into common stock is subject to stockholder approval.

Management Comments

• Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Industry Context

Private placements are a common method for companies, especially in the biotech sector, to raise capital from institutional investors. This transaction reflects continued investment interest in Oruka Therapeutics.

Comparison to Industry Standards

• Similar private placements in the biotech industry often involve institutional investors acquiring a mix of common stock and convertible securities.
• The conversion ratio of 1,000 shares of common stock per share of preferred stock is within the typical range for convertible preferred stock offerings in the biotech sector.
• Comparable companies that have utilized private placements include [hypothetical company A] and [hypothetical company B], which raised capital for clinical trials and research and development.

Stakeholder Impact

• The private placement provides Oruka Therapeutics with additional capital, potentially benefiting shareholders through increased research and development efforts.
• The transaction could impact employee morale positively due to increased financial stability.

Next Steps

• Stockholder approval of the conversion of the Series A non-voting convertible preferred stock into shares of Common Stock.
• Potential future conversion of the Series A Preferred Stock into Common Stock.

Key Dates